Abstract
CoVID-19 is spreading throughout the world at an alarming rate. So far it has spread over 200 countries in the whole world. Mathematical modeling of an epidemic like CoVID-19 is always useful for strategic decision making, especially it is very useful to gain some understanding of the future of the epidemic in densely populous countries like India. We use a simple yet effective mathematical model SIR(D) to predict the future of the epidemic in India by using the existing data. We also estimate the effect of lock-down/social isolation via a time-dependent coefficient of the model. The model study with realistic parameters set shows that the epidemic will be at its peak around the end of June or the first week of July with almost 108 Indians most likely being infected if the lock-down relaxed after May 3, 2020. However, the total number of infected population will become one-third of what predicted here if we consider that people only in the red zones (approximately one-third of India’s population) are susceptible to the infection. Even in a very optimistic scenario we expect that at least the infected numbers of people will be 
.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
H. P. is grateful for the support of the Ramanujan Fellowship research grant under SERB-DST (SB/S2/RJN-031/2016), Government of India. V.R. acknowledges financial support from the DST through INSPIRE Faculty research grant, Government of India. VR also like to thank Prof. Sourendu Gupta for an initial discussion on SIR(D) model. SS acknowledges financial support from Polish National Agency for Academic Exchange.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
